temozolomide sun
sun pharmaceutical industries europe b.v. - temozolomide - glioma; glioblastoma - antineoplastic agents - temozolomide sun is indicated for the treatment of:adult patients with newly diagnosed glioblastoma multiforme concomitantly with radiotherapy (rt) and subsequently as monotherapy treatment;children from the age of three years, adolescents and adult patients with malignant glioma, such as glioblastoma multiforme or anaplastic astrocytoma, showing recurrence or progression after standard therapy.
athena-ondansetron odt tablet (orally disintegrating)
athena pharmaceutiques sas - ondansetron - tablet (orally disintegrating) - 4mg - ondansetron 4mg - 5-ht3 receptor antagonists
athena-ondansetron odt tablet (orally disintegrating)
athena pharmaceutiques sas - ondansetron - tablet (orally disintegrating) - 8mg - ondansetron 8mg - 5-ht3 receptor antagonists
levetiracetam 500mg5ml concentrate for solution for infusion vials
sun pharmaceutical industries europe b.v. - levetiracetam - solution for infusion - 100mg/1ml
temozolomide 5mg capsules
sun pharmaceutical industries europe b.v. - temozolomide - capsule - 5mg
temozolomide 100mg capsules
sun pharmaceutical industries europe b.v. - temozolomide - capsule - 100mg
temozolomide 140mg capsules
sun pharmaceutical industries europe b.v. - temozolomide - capsule - 140mg
temozolomide 180mg capsules
sun pharmaceutical industries europe b.v. - temozolomide - capsule - 180mg
temozolomide 20mg capsules
sun pharmaceutical industries europe b.v. - temozolomide - capsule - 20mg
temozolomide 250mg capsules
sun pharmaceutical industries europe b.v. - temozolomide - capsule - 250mg